Naoki Furuya

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Haruhiro Saito, Tatsuro Fukuhara, Naoki Furuya et al. · The Lancet Oncology · 2019 · 636 citations · Full text

Medicine, Oncology, Pharmacology +12

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With <i>EGFR</i> T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor

Hiroaki Akamatsu, Yukihiro Toi, Hidetoshi Hayashi et al. · JAMA Oncology · 2021 · 185 citations · Full text

Medicine, Oncology, Pharmacology +16

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial

Yosuke Kawashima, Tatsuro Fukuhara, Haruhiro Saito et al. · Institutional Repositories DataBase (IRDB) · 2022 · 109 citations

Medicine, Oncology, Pharmacology +14

A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis

Satoshi Ikeda, Terufumi Kato, Hirotsugu Kenmotsu et al. · Journal of Thoracic Oncology · 2020 · 103 citations · Full text

Medicine, Oncology, Pharmacology +5

Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy

Yuka Ito, Takashi Tsuda, Hiroko Minatogawa et al. · Journal of Clinical Oncology · 2018 · 72 citations

Medicine, Oncology, Pharmacology +11